Baltimore, Maryland – November 5, 2024 Auxergen’s latest research on the rapidly evolving mpox strains has been published in The Lancet Microbe. With a ranking of 2nd out of 132 in the infectious disease category, and 3rd out of 161 in the microbiology category, it is one of the world’s foremost scientific journals. Key Findings:…
Baltimore, Maryland – November 3, 2024 Unlocking the Secrets of Virus Assembly: A Breakthrough at Auxergen Exciting News! Auxergen has just published groundbreaking research in the journal Virology, revealing the secrets of virus assembly. Our study on Xanthomonas integrative filamentous phages uncovers novel packaging mechanisms that could revolutionize disease treatments and biotechnological solutions. Key Findings:…
Baltimore, Maryland – July 3, 2024 Auxergen announces the establishment of an Italian division to bring the Auxergen’s Xylella treatment to Italy and the wider E.U. Learn more at the Baltimore Business Journal Media Contact: Michael Feehley michael@auxergen.com 443.929.9757
Rome, Italy – May 20, 2024 Today, Auxergen had a productive meeting with Coldiretti leadership to discuss our groundbreaking bacteriophage solution, designed to combat Olive Quick Decline Syndrome (OQDS). Coldiretti, the leading agricultural business association in Italy with over 1.6 million members, is a champion of sustainable agriculture and food systems. Their commitment to supporting…
San Diego, California – March 18, 2024 Auxergen Inc., an innovator in biotechnology based in Maryland, proudly announces its selection for a coveted presentation slot at the esteemed BIO International Convention 2024, happening from June 3-6 at the San Diego Convention Center. This event, known as the world’s largest gathering for the biotechnology industry, brings together…
Baltimore, Maryland – March 11, 2024 Auxergen announces its latest product: an in-vitro assay to measure the pharmacokinetics of THC, CBD and like cannabinoids, which promises to revolutionize the field of cannabis research and diagnostics, with application to drug discovery, design, efficacy testing, and a host of therapeutic uses. The Auxergen cannabinoid biokinetics (CBK) assay…
Baltimore, Maryland – March 11, 2024 Auxergen, Inc. has achieved Qualified Maryland Biotechnology Company (QMBC) status for 2024. QMBC status provides early-stage biotechnology companies with refundable tax credits to help offset high research and development costs. Auxergen develops phage-based cures for agricultural, environmental, and human diseases. The company is currently fielding a bio-control solution to combat the…
At Auxergen, we are thrilled to share a promising update on our XylePhage project, a revolutionary endeavor aiming to safeguard a 95% of the world’s olive oil production currently threatened by the perilous Olive Quick Decline Syndrome (OQDS).
443.887.4110
info@auxergen.com
Rita Rossi Colwell Center
701 East Pratt Street, Baltimore, MD 21202
